Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 14,927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disorders Clear all
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

NCT03806127
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 22, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

NCT07595874
View directory record Official record
Conditions
Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Magnetic Resonance Imaging
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Goodyear, Arizona • Corona, California • Duarte, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA

NCT01550510
View directory record Official record
Conditions
Stage IV Colorectal Cancer
Interventions
Ascorbic Acid, Irinotecan
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Phase 1 Interventional

Sirolimus for Eosinophil-Associated Gastrointestinal Disorders

NCT01814059
View directory record Official record
Conditions
Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
Interventions
sirolimus
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

NCT00114179
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
capecitabine, radiation therapy, bevacizumab, therapeutic conventional surgery, gemcitabine hydrochloride
Drug · Radiation · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 22, 2026, 4:55 PM EDT
Completed No phase listed Observational

Intraperative Assessment of Renal Perfusion Using Infrared Imaging

NCT00595179
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population

NCT01385579
View directory record Official record
Conditions
Malignant Neoplasm of Large Intestine
Interventions
Care manager outreach
Other
Lead sponsor
Northwestern University
Other
Eligibility
50 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

NCT01381562
View directory record Official record
Conditions
Infections, Intestinal
Interventions
Drug: GSK2251052, Meropenem, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Mobile, Alabama • Long Beach, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

NCT00645710
View directory record Official record
Conditions
Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
gemcitabine hydrochloride, floxuridine, proteomic profiling, matrix-assisted laser desorption/ionization time of flight mass spectrometry, liquid chromatography, yttrium Y 90 anti-CEA monoclonal antibody cT84.66, laboratory biomarker analysis, mass spectrometry, pharmacological study
Drug · Genetic · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 22, 2026, 4:55 PM EDT
Active, not recruiting Phase 1 Interventional

SIRT With Tremelimumab and Durvalumab for Resectable HCC

NCT05701488
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Durvalumab, Tremelimumab, SIRT
Drug · Device
Lead sponsor
Jiping Wang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 4:55 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Cryotherapy for GAVE

NCT04760873
View directory record Official record
Conditions
GAVE - Gastric Antral Vascular Ectasia, Bleeding, Bleeding Gastric
Interventions
cryotherapy
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
5
States / cities
Tampa, Florida • New Hyde Park, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated No phase listed Observational

Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

NCT03073473
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Melanoma, Metastatic Prostate Cancer
Interventions
NantHealth GPS Cancer Test
Diagnostic Test
Lead sponsor
Cota Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
East Brunswick, New Jersey • Freehold, New Jersey • Hackensack, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 22, 2026, 4:55 PM EDT
Enrolling by invitation No phase listed Observational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

NCT06262282
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions
mycobacteriophage
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Not applicable Interventional

GIST and Memory and Attention Adaptation Training

NCT04879979
View directory record Official record
Conditions
GIST, Malignant, CBT
Interventions
MAAT
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 22, 2026, 4:55 PM EDT
Withdrawn No phase listed Observational

Immunology of HIV and Alcoholic Hepatitis

NCT03951662
View directory record Official record
Conditions
HIV/AIDS, Alcoholic Hepatitis
Interventions
Alcoholic Hepatitis Group, Heavy Drinking Controls without Hepatitis
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 22, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations

NCT03726827
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver, Fatty Liver
Interventions
Fibroscan screening
Other
Lead sponsor
Fatty liver Foundation
Other
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Texas City, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

NCT02978339
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Curcumin
Drug
Lead sponsor
John E. Eaton
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Not applicable Interventional

Effectiveness of Biofeedback-Assisted Relaxation Training in Children With Eosinophilic Duodenitis

NCT00124501
View directory record Official record
Conditions
Abdominal Pain, Duodenitis
Interventions
Biofeedback-assisted relaxation training
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2008 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

NCT04530981
View directory record Official record
Conditions
GIST - Gastrointestinal Stromal Tumor
Interventions
Ripretinib, Repaglinide
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • Miami, Florida • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Early Phase 1 Interventional

A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula

NCT02423330
View directory record Official record
Conditions
Anal Fistula, Rectal Fistula, Fistula in Ano, Transsphincteric Fistula
Interventions
Strattice-LIFT
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
22 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 22, 2026, 4:55 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

NCT00835328
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin (9-39), Vehicle
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
Up to 12 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas

NCT00006467
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ISIS 2503, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
16
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 22, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

NCT00297167
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 22, 2026, 4:55 PM EDT
Recruiting Not applicable Interventional

A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis

NCT05579392
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Bright Light Therapy, Placebo Retimer Device
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 4:55 PM EDT